Xconomy: Elliott Sigal, Bristol’s Former R&D Chief, on Life After Big Pharma

▤ Summary

Elliott Sigal, Bristol’s Former R&D Chief, on Life After Big Pharma (Page 3 of 3) when they can and should take on something their own, when they can partner, when they can bring other people in.People don’t realize that 50 percent of patients with congestive heart failure die within five years.ES: I wouldn’t want to say it’s hype, but this new technology of gene editing which goes under the acronym of CRISPR is very, very interesting.Bristol has a wonderful program in hepatitis C. It wasn’t even named when I was in medical school, now they are curing that disease.Picking the right person for the right role, or [not] funding something that had higher risk at the time than I felt I could take, yet eventually it worked out.

▦ Linked Companies

Shareaholic

$1M to $5M